Search Orphan Drug Designations and Approvals
-
Generic Name: | copanlisib | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | ALIQOPA | ||||||||||||||||
Date Designated: | 02/05/2015 | ||||||||||||||||
Orphan Designation: | Treatment of follicular lymphoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Bayer US LLC 100 Bayer Boulevard P. O. Box 915 Hanover, New Jersey 07981 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | copanlisib |
---|---|---|
Trade Name: | ALIQOPA | |
Marketing Approval Date: | 09/14/2017 | |
Approved Labeled Indication: | Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies | |
Exclusivity End Date: | 09/14/2024 | |
Exclusivity Protected Indication* : | Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-